This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Updated from 1:56 p.m. EST

Shares of V.I. Technologies (VITX) were among the best-performing health and pharmaceutical stocks Thursday, rising 69.6% after the company's merger partner received fast-track status from the Food and Drug Administration for its HIV drug.

Privately held Panacos Pharmaceuticals, which plans to merge with V.I during the first quarter of 2005, said the oral drug was well tolerated during phase Ia and phase Ib studies. Full results will be presented at a conference in February. In December, the company initiated a phase IIa trial of PA-457. Results from the trial are expected during the second quarter of 2005. Shares traded up 48 cents to $1.17.

Icon (ICLR) fell 3.5% after the company posted second-quarter results that beat expectations but warned that full 2005 results would fall short. The clinical research organization posted earnings of 41 cents a share during the second quarter on sales of $79.5 million. Analysts polled by Thomson First Call were expecting earnings of 40 cents a share on sales of $75.9 million. Looking ahead, Icon forecast 2005 earnings of $1.68 to $1.70 a share. Previously, the company forecast earnings of $2 to $2.10 a share. Analysts had been expecting earnings of $2.03 a share. Shares traded down $1.25 to $35.

Shares of Osteotech (OSTE) fell 10.8% after the company cut its 2004 sales outlook and said a writedown would cause it to post a bigger loss than expected. The $5.8 million writedown will now result in the company posting a loss of 28 cents to 31 cents a share. Previously, Osteotech said it would post a loss of 2 cents to 5 cents a share.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,765.10 -13.05 -0.07%
S&P 500 2,064.25 +3.02 0.15%
NASDAQ 4,756.8210 +8.4250 0.18%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs